The latest update is out from Lexeo Therapeutics, Inc. (LXEO).
Tim Van Hauwermeiren joined the board of Lexeo Therapeutics, Inc. on July 5, 2024, bringing a wealth of experience from his tenure as CEO of argenx SE and board service at other biopharmaceutical companies. His directorship, which will be compensated with cash and stock options, is set to last until the 2027 Annual Meeting of Stockholders. Van Hauwermeiren has no familial ties to the company’s leadership and is covered by a standard indemnification agreement, with no material interests in any company transactions. The company publicly announced his appointment shortly after.
See more data about LXEO stock on TipRanks’ Stock Analysis page.
